| Ticker Details |
Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company. It is engaged in the acquisition, development and commercialization of products to enhance cancer care. Its drug candidates are PB272 (neratinib, oral), PB272 (neratinib, intravenous), and PB357.
|
| IPO Date: |
April 20, 2012 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$344.17M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$1.20 | 3.11%
|
| Avg Daily Range (30 D): |
$0.15 | 2.20%
|
| Avg Daily Range (90 D): |
$0.14 | 2.44%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.6M |
| Avg Daily Volume (30 D): |
.36M |
| Avg Daily Volume (90 D): |
.4M |
| Trade Size |
| Avg Trade Size (Sh.): |
117 |
| Avg Trade Size (Sh.) (30 D): |
71 |
| Avg Trade Size (Sh.) (90 D): |
78 |
| Institutional Trades |
| Total Institutional Trades: |
3,695 |
| Avg Institutional Trade: |
$2.06M |
| Avg Institutional Trade (30 D): |
$.56M |
| Avg Institutional Trade (90 D): |
$.73M |
| Avg Institutional Trade Volume: |
.05M |
| Avg Institutional Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.63M |
| Avg Closing Trade (30 D): |
$.51M |
| Avg Closing Trade (90 D): |
$1M |
| Avg Closing Volume: |
77.33K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
|
$.18
|
$.12
|
|
Diluted EPS
|
|
$.17
|
$.12
|
|
Revenue
|
|
$54.48M
|
$52.44M
|
|
Gross Profit
|
|
$42.3M
|
$40.14M
|
|
Net Income / Loss
|
|
$8.84M
|
$5.86M
|
|
Operating Income / Loss
|
|
$9.57M
|
$6.64M
|
|
Cost of Revenue
|
|
$12.17M
|
$12.3M
|
|
Net Cash Flow
|
|
$-1.14M
|
$-8.37M
|
|
PE Ratio
|
|
|
|
|
|
|
